The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
W Tang, Z Chen, W Zhang, Y Cheng, B Zhang… - Signal transduction and …, 2020 - nature.com
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
J Chen, R **, J Zhao, J Liu, H Ying, H Yan, S Zhou… - Cancer letters, 2015 - Elsevier
Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …
Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects
Chronic liver dysfunction or injury is a serious health problem worldwide. Chronic liver
disease involves a wide range of liver pathologies that include fatty liver, hepatitis, fibrosis …
disease involves a wide range of liver pathologies that include fatty liver, hepatitis, fibrosis …
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Z Cheng, J Wei-Qi, D ** - Biochimica et Biophysica Acta (BBA)-Reviews …, 2020 - Elsevier
Liver cancer is highly malignant and insensitive to cytotoxic chemotherapy and is associated
with very poor patient prognosis. In 2007, the small-molecule targeted drug sorafenib was …
with very poor patient prognosis. In 2007, the small-molecule targeted drug sorafenib was …
Infection and cancer in multicellular organisms
PW Ewald, HA Swain Ewald - … Transactions of the …, 2015 - royalsocietypublishing.org
Evolutionary considerations suggest that oncogenic infections should be pervasive among
animal species. Infection-associated cancers are well documented in humans and domestic …
animal species. Infection-associated cancers are well documented in humans and domestic …
[HTML][HTML] ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system
C Zuo, X Sheng, M Ma, M **a, L Ouyang - Oncotarget, 2016 - ncbi.nlm.nih.gov
The interferon-stimulated gene 15 ubiquitin-like modifier (ISG15) encodes an IFN-inducible,
ubiquitin-like protein. The ISG15 protein forms conjugates with numerous cellular proteins …
ubiquitin-like protein. The ISG15 protein forms conjugates with numerous cellular proteins …
Risk factors for early mortality after hepatectomy for hepatocellular carcinoma
CW Lee, HI Tsai, CM Sung, CW Chen, SW Huang… - Medicine, 2016 - journals.lww.com
Risk factors for early mortality after hepatectomy for hepat... : Medicine Risk factors for early
mortality after hepatectomy for hepatocellular carcinoma : Medicine Log in or Register Get …
mortality after hepatectomy for hepatocellular carcinoma : Medicine Log in or Register Get …
Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection
M Zhang, D Wang, H Liu, H Li - Infectious Agents and Cancer, 2018 - Springer
Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as
the first-line choices regarding the treatment of chronic hepatits B. The impact of the two …
the first-line choices regarding the treatment of chronic hepatits B. The impact of the two …
The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes …
ZQ Li, CL Hu, P Yu, XY Gu, JJ Zhang, H Li… - Clinics and Research in …, 2017 - Elsevier
Background Patients with chronic hepatitis B virus (HBV) infection are at high risk for
progressing to decompensated cirrhosis and hepatocellular carcinoma (HCC). Although …
progressing to decompensated cirrhosis and hepatocellular carcinoma (HCC). Although …
Comparing the clinicopathological characteristics of combined hepatocellular–cholangiocarcinoma with those of other primary liver cancers by use of the updated …
Aims Combined hepatocellular–cholangiocarcinoma (cHCC‐CCA) is an uncommon hepatic
malignancy with a poor outcome. The 2019 World Health Organization (WHO) classification …
malignancy with a poor outcome. The 2019 World Health Organization (WHO) classification …